A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) — Stella
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
China
Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928, Beijing, Beijing Municipality
Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian
Sun Yat-Sen University Cancer Center /ID# 262092, Guangzhou, Guangdong
Nanfang Hospital of Southern Medical University /ID# 262091, Guangzhou, Guangdong
Harbin Medical University Cancer Hospital /Id# 262070, Harbin, Heilongjiang
Henan Cancer Hospital /ID# 262098, Zhengzhou, Henan
Hubei Cancer Hospital /ID# 262030, Wuhan, Hubei
The Second Affiliated Hospital of Nanchang University /ID# 262085, Nanchang, Jiangxi
Liaoning Cancer Hospital & Institute /ID# 268023, Shenyang, Liaoning
Zhongshan Hospital Fudan University /ID# 262135, Shanghai, Shanghai Municipality
Zhejiang Cancer hospital /ID# 262046, Hangzhou, Zhejiang